In June 2021, Novo Nordisk won FDA approval for Ozempic's sibling, Wegovy, both of which share the same active ingredient (semaglutide), as a treatment for chronic weight management. The rest, as ...

“For three years – that’s how long this wonder drug has been in shortage – they’ve been compounding copies of semaglutide injection for patients at a time when Novo Nordisk could not ...

Novo Nordisk has been on the hunt for differentiated obesity drugs that could complement its blockbuster GLP-1 agonist, Wegovy. It’s found a contender with preclinical data indicating it can ...

Novo Nordisk said the data on 10 deaths and more than 100 hospitalizations came from the US Food and Drug Administration’s adverse event reporting database for semaglutide; the FDA warns that ...

Novo Nordisk NOVO.B0.48%increase; green up pointing triangle said the Food and Drug Administration accepted its submission of a new drug application for a Wegovy pill to treat obesity amid a tense ...

Hims & Hers started prescribing compounded semaglutide, the active ingredient in Novo Nordisk's diabetes drug Ozempic and Wegovy, in May of 2024. The company has largely had to stop offering the ...

April 14 (Reuters) - Danish drugmaker Novo Nordisk ... known as semaglutide, has given rise to concerns about unregulated, compounded and counterfeit medicines. Its weight-loss drug Wegovy also ...

FRANKFURT, Germany — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy ... on the same basic ingredient, semaglutide. At the peak, the company's ...